Takeda, KINAXO Extend Research Pact

KINAXO Biotechnologies GmbH has entered a second collaboration with Takeda Pharmaceutical Co., under which KINAXO will apply its PhosphoScout technology to assist research of Takeda’s drugs under development. The goal of the collaboration is to allow Takeda to make early decisions on drug efficacy and safety. Financial details were not disclosed.

PhosphoScout enables quantitative analysis of cellular phosphoproteomes on a global scale and provides valuable insights into a drug’s mode of action. PhosphoScout can also identify differentially regulated phosphorylation sites in vivo that may serve as pharmacodynamic or drug response biomarkers in clinical trials.

Dr. Andreas Jenne, KINAXO’s chief executive officer said: “We are very pleased to continue our collaboration with Takeda, a world leading healthcare company, and look forward to supporting Takeda’s efforts in developing drugs. This collaboration once again demonstrates the power of our PhosphoScout platform in drug discovery and development.”